Latest Lucentis Stories
Desire for Greater Efficacy and Improved Convenience Drive Perceived Value of Emerging Therapies for Wet Form of the Disease, According to Findings from Decision Resources Group BURLINGTON,
TARRYTOWN, N.Y., Oct. 17, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
-- Fourth indication for injection treatment that can stabilize and improve vision(1) -- mCNV a leading cause of visual impairment among those 20-50 years of age(9) Since
Fovista and Abicipar Pegol Will Need to be Priced Competitively to Current Agents to Garner Favorable Tier Placement, According to Findings from Decision Resources Group BURLINGTON, Mass.,
VANCOUVER, June 9, 2014 /PRNewswire/ - iCo Therapeutics Inc.
LONDON, May 15, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
An anti-cancer drug has been proven to be equally as effective in treating the most common cause of blindness in older adults as a more expensive drug specifically formulated for this purpose.
- totally perplexed and mixed up.